CRISPR–Cas3 Genome-Editing System Holds Therapeutic Potential
Researchers at the University of Tokyo demonstrated that the CRISPR‑Cas3 system can permanently suppress transthyretin (TTR) production in a mouse model of hereditary amyloidosis. Using lipid‑nanoparticle delivery, they achieved roughly 48% editing of hepatic TTR alleles and an 80% reduction in circulating TTR protein after a single dose. The Cas3 approach generated extensive, precise deletions without detectable off‑target indels, addressing a key safety concern of CRISPR‑Cas9. The findings suggest a viable, potentially curative gene‑editing platform for ATTR and other inherited disorders.
Dycem, a contamination‑control specialist, celebrates 60 years since its 1966 founding, tracing roots to a high‑friction polymer discovered in 1960. The company grew from niche non‑slip products to global cleanroom solutions, now present in more than 50 countries and 30,000...
Nonlinear X-Ray Four-Photon Interaction Unveiled
Researchers have reported the first experimental observation of a nonlinear X‑ray four‑photon interaction, a phenomenon previously confined to theoretical models. The breakthrough was achieved using ultra‑intense pulses from a free‑electron laser, enabling simultaneous absorption of four X‑ray photons in a...
Jazz Sells Priority Review Voucher for $200M, Scoring Highest Price in a Decade
Jazz Pharmaceuticals announced the sale of a priority review voucher to an undisclosed buyer for $200 million, marking the highest price paid for such a voucher in a decade. The voucher, originally granted for developing a treatment for a neglected disease,...
Health Tech Funding Rounds Get Bigger when Andreessen Horowitz and General Catalyst Join
Rock Health’s latest report shows a handful of venture firms dominate health‑tech financing. When Andreessen Horowitz and General Catalyst join a round, the deal size expands dramatically, with average rounds climbing from roughly $30 million to $50 million. Together these two firms...
Program Harnesses the Power of Mentorship for Patient Organization Leaders
The Milken Institute’s FasterCures LeadersLink program, launched in 2020, provides mentorship, peer learning, and capstone projects for emerging leaders of patient advocacy organizations that fund or conduct biomedical research. The cohort‑based model connects mentees with seasoned executives, fostering strategic reflection...
A CRISPR Fingerprint of Pathogenic C. Auris Fungi for Precision Diagnostics
Researchers at Harvard’s Wyss Institute have unveiled dSHERLOCK, a digital CRISPR‑based diagnostic that can detect and quantify Candida auris from swab samples in under 40 minutes while simultaneously identifying antifungal resistance mutations. The platform merges SHERLOCK’s single‑nucleotide precision with single‑molecule...
Natural Fiber Welding Receives Investment From Provest Equity Partners and CTW Venture Partners
Natural Fiber Welding, a Peoria‑based developer of plant‑derived performance materials, secured a strategic investment from Provest Equity Partners and CTW Venture Partners. The undisclosed capital infusion coincides with Suhas Uppalapati joining the board as Chairman. The company will deploy the...
JPM26: Gilead Captures Sunny JPM Mood With Yeztugo Numbers, HIV Vibes
Gilead’s new HIV therapy Yeztugo is gaining rapid market traction, achieving 85% payer coverage six months after its June 2025 approval and hitting the $150 million revenue target for the year. CEO Daniel O’Day highlighted voluntary licensing of the drug’s active ingredient,...
2026 Outlook: ‘Slow-Moving Catastrophe’ at FDA
The FDA is entering a ‘slow‑moving catastrophe’ as staffing cuts, politicization, and the erosion of scientific expertise undermine its regulatory capacity. Senior leadership turnover and a hiring freeze have reduced review staff by roughly 15 percent, while political pressure accelerates...
Framework to Optimize Mammalian Cell Culture Media Blending
Researchers from Osaka University and Shimadzu introduced a mathematically precise workflow for chemically defined media (CDM) blending in mammalian cell culture. The three‑step process combines experimental design, cell culture testing, and regression modeling, using PCA to eliminate multicollinearity and D‑optimal...
Drugs From the Deep
Marine organisms have yielded over 40,000 natural compounds, with 13 now FDA‑approved for cancers, viral infections and chronic pain. The primary obstacle to expanding this "blue pharmaceutical" pipeline is supply, as many bioactive molecules occur in minute quantities that are...
Biologics Manufacturers Urged to Develop QC Plans Early
At an upcoming conference, French biotech consultancy INITS will urge biologics manufacturers to establish a chemistry, manufacturing and controls (CMC) management strategy for reference materials early in development. Regulators increasingly demand deep characterization of reference material, especially by Phase III, and...
Regulatory Support Helping Biopharma to Embrace Platform Technologies
Biopharma firms are increasingly adopting platform technologies—standardized manufacturing bases that can be customized with disease‑specific modules—to accelerate product development and cut costs. Experts cite the lipid nanoparticle system used for mRNA vaccines as a prime example, where swapping the mRNA...
Pharmacovigilance Awareness Among Saudi Healthcare Students
A recent cross‑sectional study surveyed 500 Saudi pharmacy and medical students to gauge their understanding of pharmacovigilance (PV). Only 35% demonstrated sufficient knowledge of adverse drug reaction (ADR) reporting, revealing significant curriculum gaps. The researchers recommend integrating mandatory PV modules...
Intermittent Hypobaric Pressure Fights Aging and Osteoporosis
A recent preclinical study demonstrates that intermittent hypobaric pressure (IHP) exposure can mitigate age‑related bone loss and reverse cellular aging markers. Mice subjected to 2‑hour hypobaric cycles three times a week showed a 12% increase in bone mineral density and...
ImmunityBio's Anktiva Lung Cancer Data; Glaukos' Glaucoma Implant Sales Disappoint
ImmunityBio announced that its lymphocyte‑stimulating agent Anktiva, combined with checkpoint inhibitors, restored immune cells and produced objective responses in a non‑small‑cell lung cancer (NSCLC) study. The data suggest the combination could enhance the efficacy of existing immunotherapies. Meanwhile, Glaukos reported...
First-Time Use of AI for Genetic Circuit Design Demonstrated in a Human Cell Line
Rice University researchers unveiled CLASSIC, a high‑throughput platform that couples long‑ and short‑read sequencing to generate millions of genetic‑circuit designs in human cells. By pairing this massive library with machine‑learning models, the team demonstrated the first AI‑driven design of functional...
Thermo Fisher to Lay Off 421 Workers as It Winds Down Lab Product Site in North Carolina
Thermo Fisher Scientific announced it will phase out operations at its laboratory products facility in Asheville, North Carolina, laying off 421 workers. The shutdown is slated to be completed by the end of 2026, ending the site’s production of consumables...
Hydrogel Cilia Set New Standard in Microrobotics
Scientists at the Max Planck Institute, HKUST and Koç University have created 18 µm hydrogel cilia that beat at 5‑40 Hz when driven by a 1.5 V electric field. Using two‑photon polymerization, they printed arrays of hundreds of these microactuators on a flexible substrate...
The AbbVie Strategy, a Company at an Inflection Point
AbbVie’s historic reliance on Humira has been upended by a 54.5% U.S. revenue drop as biosimilars entered in 2023, prompting a strategic pivot toward its next‑generation immunology drugs Skyrizi and Rinvoq. The company projects combined revenue of over $31 billion from...
FDA Seeks Changes to GLP-1, Flu Shot Labels
The FDA has asked manufacturers of GLP‑1 weight‑loss drugs, including Wegovy, Saxenda and Zepbound, to drop the suicide‑ideation warning after a comprehensive safety review found no elevated risk. The agency’s meta‑analysis of 91 trials involving more than 100,000 participants confirmed...
AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Product Launches
At the J.P. Morgan Healthcare Conference, AstraZeneca reaffirmed its ambition to generate $80 billion in revenue by 2030, a target now seen as attainable. The company highlighted three near‑term product launches—baxdrostat for hypertension, camizestrant for breast cancer, and gefurulimab for myasthenia...
Super-Resolution Ultrasound Reveals Brain Issues in Parkinson’s
A new super‑resolution ultrasound technique can visualize microvascular abnormalities in the brains of Parkinson's patients with unprecedented clarity. In a study of 120 early‑stage participants, the method identified vascular biomarkers up to five years before clinical symptoms appeared. The non‑invasive...
Hippocratic AI Builds in Life Sciences with Grove AI Buy
Hippocratic AI announced the acquisition of Grove AI, a pharma‑R&D specialist, and launched a dedicated life‑sciences division headed by Dr Ahad Wahid. The move adds the Grace agent, which automates clinical‑trial tasks, to Hippocratic's safety‑first generative AI portfolio. The company,...
#JPM26: Day 3 at the JP Morgan Healthcare Conference
Day three of the JPMorgan Healthcare Conference saw sessions winding down as investors turned their attention to key presentations, notably from Chinese contract research giant WuXi AppTec. The company used its slot to unveil a refreshed drug‑development platform and hint...
#JPM26: Q&A with Bristol Myers Squibb CEO Chris Boerner on 2026 Outlook
Chris Boerner, in his third year as Bristol Myers Squibb CEO, opened the JPMorgan Healthcare Conference with a forward‑looking Q&A on the company’s 2026 outlook. He outlined a $45 billion revenue target, driven by late‑stage oncology and immunology assets, while emphasizing...
JPM: Illumina Launches 'Unprecedented' Disease Biology Atlas
Illumina unveiled the Billion Cell Atlas, a genome‑wide perturbation database that profiles 20,000 genes across 250 disease‑relevant human cell types using CRISPR. The initial release contains data from 150 million cells and aims to expand to five billion cells within three years,...
AstraZeneca Bets on In-House AI to Speed up Oncology Research
AstraZeneca is acquiring Boston‑based Modella AI to bring its pathology‑focused models, data, and talent directly into the company’s oncology research pipeline. The move shifts the relationship from a collaborative partnership to full ownership, aiming to embed AI in quantitative pathology,...
UK Names Health Data Chief, as BIA Finds Its New CEO
Former Moderna executive Dr Melanie Ivarsson has been named chief executive of the UK Health Data Research Service, a £600 million government‑backed unit that will create a secure, single gateway to NHS health data. The HDRS, based at the Wellcome Genome...
Antimicrobial Polymer Nanocomposites Made with Beetroot
A study in *Materials* shows that copper nanoparticles produced via a beetroot‑based green synthesis exhibit markedly stronger antimicrobial activity when embedded in polypropylene than both silver‑based composites and chemically reduced copper. The green‑synthesized copper particles are smaller, less prone to...
New Drug Candidate Reverses Metabolic Liver Disease and Fibrosis
Researchers at McMaster University, in partnership with Espervita Therapeutics, reported preclinical data showing that the small‑molecule EVT0185 can both prevent and reverse liver fibrosis in mouse models of metabolic dysfunction‑associated steatohepatitis (MASH). The compound simultaneously inhibits the enzymes ACLY and...
Nabla: Using AI to ‘Auto-Complete’ Biologics Design
Nabla Bio, a Harvard spin‑out founded in 2020, is developing an AI‑driven platform that automatically completes biologics designs while preserving manufacturability. The technology, created in George Church’s lab, targets the persistent bottleneck of translating complex protein candidates into scalable therapeutics....
New Method Allows Scientists to 3D-Print Structures Within Cells
Scientists have developed a technique to 3D‑print micrometer‑scale structures inside living cells using a light‑sensitive photoresist and two‑photon laser polymerization. The method achieves sub‑micron resolution, allowing shapes such as barcodes, geometric patterns, and a miniature elephant to be fabricated intracellularly....
Astaxanthin’s Role in Easing Exercise Muscle Damage
A recent study highlights astaxanthin’s antioxidant properties in mitigating exercise‑induced muscle damage. Participants who took a daily 12 mg dose experienced lower oxidative stress markers and reported faster recovery from soreness. The research covered both endurance and resistance training protocols, showing...
Virtual Scientists Poised to Accelerate Discovery
AI‑driven virtual scientists are moving from prototype to production as Potato’s AI agent, Tater, replicated a core neuroscience finding and pinpointed SARS‑CoV‑2 protease mutations within hours. The company closed a $4.5 million seed round and partnered with Wiley to ingest peer‑reviewed...
Building Intelligent Workflows for the Multiomic Era
Genomics is shifting from manual, bottlenecked processes to automated, modular workflows that can keep pace with rapidly evolving assays. Companies such as Opentrons, 10x Genomics, and SPT Labtech are delivering flexible robotic platforms that reconfigure library‑prep and single‑cell pipelines on...
Mapping the Next Phase of Analytical Innovation for ADCs
Antibody‑drug conjugates (ADCs) are reshaping oncology, but their structural heterogeneity creates demanding bioanalytical and pharmacokinetic challenges. WuXi AppTec’s DMPK leaders stress that precise drug‑to‑antibody ratio (DAR) measurement, payload release profiling, and biotransformation mapping are essential across development stages. They recommend...
Novartis Doesn’t Have a GLP-1. They Don’t Miss It In a World Of Me-Toos
Novartis chief strategy officer Ronny Gal told BioSpace at J.P. Morgan that the Swiss giant will not pursue a GLP‑1 acquisition, citing the high commercial risk of me‑too products. He emphasized that existing GLP‑1s such as Eli Lilly’s Zepbound and Novo Nordisk’s...
MS Linked to EBV Infection Through Cross-Reactive T Cells
Researchers at Karolinska Institutet discovered that CD4+ T cells targeting Epstein‑Barr virus (EBV) protein EBNA1 also recognize the brain protein Anoctamin‑2 (ANO2), providing mechanistic evidence linking EBV infection to multiple sclerosis (MS). In blood samples, about 57% of untreated MS...
Lesion-Targeted, Severity-Responsive Nanoparticle Delivery for RNA Therapy in Osteoarthritis
Researchers introduced Matrix‑Inverse Targeting (MINT) nanoparticles that exploit cartilage matrix changes to deliver RNA therapeutics directly to osteoarthritic lesions. The particles sense lesion severity, releasing siRNA or mRNA only in damaged zones, which in animal models halted cartilage degeneration and...
Uncovering a Hidden Mechanism in Met Receptor Activation
Researchers at Kanazawa University and collaborators uncovered a hidden activation mechanism for the Met receptor, showing that hepatocyte growth factor (HGF) binding to the membrane‑distal Sema domain drives dimerization of the membrane‑proximal IPT4 domains. Using in‑cell cross‑linking, high‑speed atomic force...
New Insights Into Oligoasthenozoospermia Research
A recent peer‑reviewed study uncovers novel molecular mechanisms behind olig oasthenozoospermia, the condition characterized by low sperm count and poor motility. Researchers identified mitochondrial DNA deletions and altered microRNA expression as key contributors, and demonstrated that antioxidant therapy partially restores sperm...
Starch Sachets Release Fertilizer in a Controlled Manner and Can Replace Petroleum-Derived Polymers
Brazilian researchers have created biodegradable starch sachets reinforced with copper‑zeolite nanoparticles to deliver granular fertilizers in a controlled manner. The sachets release nutrients gradually, reducing leaching and volatilization while offering antimicrobial protection against soil fungi. Mechanical strength peaks at 3 %...
Portable Device Enables Rapid Pathogen Detection in Diverse Field Environments
Purdue University engineers have unveiled IsoHeat, a portable water‑bath system that powers loop‑mediated isothermal amplification (LAMP) assays for rapid pathogen detection. The device reaches the required 65 °C in roughly 12 minutes—about one‑third the time of a leading commercial precision cooker—while...
FDA Delays Decision on Expanding Label for Travere's Kidney Disorder Drug
The FDA has extended its review of Travere Therapeutics’ kidney‑disorder drug by three months, pushing the expected decision past today’s deadline. The agency’s delay pertains to a pending label expansion for a rare renal condition, which could broaden the drug’s...
Indonesian Propolis Extract Reduces Liver Inflammation From Diet
Indonesian researchers have demonstrated that a standardized propolis extract markedly reduces diet‑induced liver inflammation in a mouse model. The study showed significant drops in pro‑inflammatory cytokines such as TNF‑α and IL‑6 without observable toxicity. Findings suggest the extract could serve...
Cyanobacteria Can Utilize Toxic Guanidine as a Nitrogen Source
Cyanobacteria have been shown to import and metabolize guanidine, using it as their sole nitrogen source. The study identified a high‑affinity ABC transporter, a guanidine hydrolase, and a riboswitch that together regulate uptake, degradation, and efflux. These mechanisms are widespread...
Single-Use Systems Enable Commercial-Scale CGT Manufacturing
Single-use systems (SUS) are becoming integral to cell and gene therapy (CGT) manufacturing, offering pre‑sterilized, disposable components that eliminate cleaning validation and enable fast changeovers for low‑volume, high‑value products. Automation and modular platforms are now being paired with SUS to...
Industry Outlook 2026: Navigating AI, Sustainability, and Operational Resilience
Pharma leaders say 2026 will be defined by the rise of agentic AI, sustainable manufacturing, and resilient, regionalized supply chains. AI agents are moving from pilot projects to embedded decision‑making in drug discovery, process optimization and digital twins, slashing timelines...
